Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00BPE
|
|||
| Former ID |
DIB003573
|
|||
| Drug Name |
AVE-1642
|
|||
| Synonyms |
EM-164; Anti-IGF-1 receptor antibody (cancer), Aventis; Anti-IGF-1 receptor antibody (cancer), ImmunoGen; Anti-insulin-like growth factor-1 receptor antibody, Aventis; Anti-insulin-like growth factor-1 receptor antibody, ImmunoGen; Anti-IGF-1 receptor antibody (cancer), sanofi-aventis; Anti-insulin-like growthfactor-1 receptor antibody, sanofi-aventis
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Discontinued in Phase 2 | [1] | |
| Company |
ImmunoGen Inc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021953) | |||
| REF 2 | Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growthfactor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5445-56. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.